Press Releases Fortress Biotech, Inc.

Equities

FBIO

US34960Q3074

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-17 pm EDT			5-day change	1st Jan Change
1.93 ^USD	+9.66%		+15.57%	-35.88%

May. 15	Earnings Flash (FBIO) FORTRESS BIOTECH Posts Q1 Revenue $13M	MT
May. 14	Fortress Biotech Says First Patient Dosed in Phase 2 Study of Triplex	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Fortress Biotech to Participate in the Alliance Global Partners’ (A.G.P.) Virtual Healthcare Company Showcase	May. 16	AQ
Fortress Biotech: Q1 Earnings Snapshot	May. 15	AQ
Fortress Biotech Reports First Quarter 2024 Financial Results and Recent Corporate Highlights	May. 15	AQ
Journey Medical Corporation to Participate in the Alliance Global Partners’ (A.G.P.) Virtual Healthcare Company Showcase	May. 15	AQ
Fortress Biotech Announces First Patient Dosed in Multi-Center Phase 2 Study of Triplex for Control of CMV in Patients Undergoing Liver Transplantation	May. 14	AQ
Journey Medical Corporation Reports First Quarter 2024 Financial Results and Recent Corporate Highlights	May. 13	AQ
Journey Medical Corporation to Announce First Quarter 2024 Financial Results on May 13, 2024	May. 07	AQ
Journey Medical Corporation Appoints Joseph Benesch as Chief Financial Officer	May. 01	AQ
Avenue Therapeutics Announces Exercise of Warrants for $4.4 Million in Gross Proceeds	Apr. 29	AQ
Journey Medical Corporation to Present at the Planet MicroCap Showcase: Vegas 2024	Apr. 25	AQ
Avenue Therapeutics Announces Reverse Stock Split	Apr. 24	AQ
Fortress Biotech Reports 2023 Financial Results and Recent Corporate Highlights	Mar. 28	AQ
Avenue Therapeutics to Host Virtual Key Opinion Leader Event on April 4, 2024	Mar. 26	AQ
Journey Medical Corporation Reports Full-Year 2023 Financial Results and Recent Corporate Highlights	Mar. 21	AQ
Journey Medical Corporation Announces U.S. FDA Acceptance of New Drug Application for DFD-29 for the Treatment of Rosacea	Mar. 18	AQ
Journey Medical Corporation to Announce Year End 2023 Financial Results on March 21, 2024	Mar. 15	AQ
Journey Medical Corporation to Participate in the 36th Annual ROTH Conference	Mar. 13	AQ
Fortress Biotech to Participate in 36th Annual ROTH Conference	Mar. 12	AQ
Journey Medical Corporation Announces Presentation of Data from Phase 1 Clinical Trial Assessing the Impact of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) on Microbial Flora of Healthy Adults at 2024 AAD Annual Meeting	Mar. 11	AQ
Fortress Biotech and Cyprium Therapeutics Announce $4.1 Million Grant from NINDS to Further Development of AAV-ATP7A Gene Therapy for Menkes Disease	Mar. 04	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Fortress Biotech, Inc.

Equities

FBIO

US34960Q3074

Press Releases

Filters